A substantial proportion of patients with rheumatoid arthritis do not respond to tumor necrosis factor blocking therapy. Results of a large genome-wide association study demonstrate evidence of novel genetic factors that determine response to treatment, which could provide a basis for individualizing therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Plant, D. et al. Genome-wide association study of genetic predictors of anti-tumour necrosis factor (TNF) treatment in rheumatoid arthritis (RA) identifies associations with polymorphisms at seven loci. Arthritis Rheum. doi:10.1002/art.30130.
Hyrich, K. L., Watson, K. D., Silman, A. J., Symmons, D. P. & British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45, 1558–1565 (2006).
van Baarsen, L. G. et al. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes Immun. 11, 622–629 (2010).
Hueber, W. et al. Blood autoantibody and cytokine profiles predict response to anti-TNF therapy in rheumatoid arthritis. Arthritis Res. Ther. 11, R76 (2009).
Marsal, S. & Julià, A. Rheumatoid arthritis pharmacogenomics. Pharmacogenomics 11, 617–619 (2010).
Coenen, M. J. et al. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 8, 761–773 (2007).
Cui, J. et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor α therapy. Arthritis Rheum. 62, 1849–1861 (2010).
van Baarsen, L. G. et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res. Ther. 12, R11 (2010).
Gonzales-Gay, M. A., Gonzalez-Juanatey, C., Vazquez-Rodriquez, T. R., Miranda-Filloy, J. A. & Llorca, J. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-α therapy. Ann. NY Acad. Sci. 1193, 153–159 (2010).
Jakobsdottir, J., Gorin, M. B., Conley, Y. P., Ferrell, R. E. & Weeks, D. E. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet. 5, e1000337 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
C. L. Verweij is a patent holder/applicant for a VU University Medical Center product.
Rights and permissions
About this article
Cite this article
Verweij, C. Anti-TNF therapy in RA—towards personalized medicine?. Nat Rev Rheumatol 7, 136–138 (2011). https://doi.org/10.1038/nrrheum.2011.13
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.13
- Springer Nature Limited
This article is cited by
-
Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis
Arthritis Research & Therapy (2019)
-
Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders
Clinical Rheumatology (2019)
-
Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis
The Pharmacogenomics Journal (2013)
-
Pharmacogenetics and pharmacogenomics in rheumatology
Immunologic Research (2013)